MedPath

NeuroNascent, Inc.

NeuroNascent, Inc. logo
🇺🇸United States
Ownership
Holding
Established
2004-01-01
Employees
1
Market Cap
-
Website
http://www.neuronascent.com

Clinical Trials

1

Active:0
Completed:1

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (100.0%)

Phase1a, Dose-escalation Study of NNI-362 in Healthy Aged Volunteers

Phase 1
Completed
Conditions
Alzheimer Disease
Interventions
Drug: Placebo
First Posted Date
2019-08-30
Last Posted Date
2023-02-17
Lead Sponsor
Neuronascent, Inc.
Target Recruit Count
56
Registration Number
NCT04074837
Locations
🇺🇸

Parexel, International, Glendale, California, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.